Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Portage Biotech Inc (OTC: PTGEF).

Full DD Report for PTGEF

You must become a subscriber to view this report.


Recent News from (OTC: PTGEF)

Portage invests in iOx Therapeutics, an United Kingdom-based cancer immunotherapy company
TORONTO , March 8, 2018 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF) , is pleased to announce that it has made an investment in iOx Therapeutics, Ltd. ("iOx"), a United Kingdom -based immuno-oncology company....
Source: PR Newswire
Date: March, 08 2018 07:00
Portage invests in Stimunity S.A, a Paris-based cancer immunotherapy company
TORONTO , Feb. 28, 2018 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF) , is pleased to announce that it has made an investment in Stimunity, SAS ("Stimunity"), a Paris -based immuno-oncology company. Portage...
Source: PR Newswire
Date: February, 28 2018 07:00
Portage 's PPL forms a joint venture with University of Glasgow to develop new peptide therapeutics
TORONTO , Feb. 2, 2018 /PRNewswire/ - Portage Biotech Inc. ("Portage") ( OTCQB: PTGEF, Canadian Stock Exchange: PBT.U ) is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ("PPL'), has formed a new joint venture company, Portage Glasgow Limited ("PGL"),...
Source: PR Newswire
Date: February, 02 2018 07:00
Portage completes distribution of stock dividend of Biohaven shares
TORONTO , Jan. 19, 2018 /PRNewswire/ - Portage Biotech Inc. ("Portage" or the "Company") ( OTCQB: PTGEF, Canadian Stock Exchange: PBT.U ) is pleased to announce that it has completed the distribution of shares of Biohaven Pharmaceutical Holding Company Ltd (BHVN:NYSE) to all eligible ...
Source: PR Newswire
Date: January, 19 2018 16:44
Portage Provides Update on Their Declaration of Stock Dividend of Biohaven Shares
Portage Provides Update on Their Declaration of Stock Dividend of Biohaven Shares Canada NewsWire TORONTO, Jan. 4, 2018 TORONTO , Jan. 4, 2018 /CNW/ -  Portage Biotech Inc. ("Portage") ( OTCQB: PTGEF, Canadian Stock Exchange: PBT.U ) announces that trading in PBT.U ...
Source: Canada Newswire
Date: January, 04 2018 13:37
Portage Announces Declaration of Stock Dividend of Biohaven Shares and Fixes January 5, 2018 as the Record Date for the Distribution and January 15, 2018 as Distribution Date
TORONTO , Dec. 4, 2017 /PRNewswire/ - Portage Biotech Inc. ("Portage") ( OTCQB: PTGEF, Canadian Stock Exchange: PBT.U ) announces that the Board of Directors of Portage has approved the previously announced distribution of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") shares...
Source: PR Newswire
Date: December, 04 2017 08:00
Important Tax Notice to U.S. Shareholders of Portage Biotech Inc.
TORONTO , Nov. 8, 2017 /PRNewswire/ - Portage Biotech Inc. ("Portage") ( OTCQB: PTGEF, Canadian Stock Exchange: PBT.U ) makes the following announcement concerning its holding of 6,341,500 common shares in Biohaven Pharmaceutical Holding Company Limited (BHVN:NYSE): This statement i...
Source: PR Newswire
Date: November, 08 2017 19:00
UPDATED : Portage announces its intention for its Biohaven shares
This update follows the press release of November 7, 2017 to provide additional detail regarding the anticipated timing of Portage's potential dividend of Biohaven shares in 2018. TORONTO , Nov. 8, 2017 /PRNewswire/ - Portage Biotech Inc. ("Portage") ( OTCQB: PTGEF, Canadian Sto...
Source: PR Newswire
Date: November, 08 2017 17:10
Portage announces its intention for its Biohaven shares
TORONTO , Nov. 7, 2017 /PRNewswire/ - Portage Biotech Inc. ("Portage") ( OTCQB: PTGEF, Canadian Stock Exchange: PBT.U ) plans to distribute as stock dividend, a substantial part of the 6,341,500 common shares it holds in Biohaven Pharmaceutical Holding Company Ltd (BHVN:NYSE). Portage w...
Source: PR Newswire
Date: November, 07 2017 19:00
Portage Biotech: An Apparent Large Discount To Liquidation Value
One of the many things I enjoy about investing is that there's always a new opportunity but also a new risk to be considered. Today, I'd like to take a narrow look at Portage Biotech Inc. (PTGEF) due to its ownership in Biohaven (BHVN) In the past, I haven't written about limited reporting e...
Source: SeekingAlpha
Date: October, 06 2017 11:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-21N/A0.10N/AN/A0
2018-08-20N/A0.10N/AN/A0
2018-08-17N/A0.10N/AN/A0
2018-08-16N/A0.10N/AN/A0
2018-08-15N/A0.10N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13120,988196,87861.4533Short
2018-08-094,00067,1045.9609Cover
2018-08-0847712,4813.8218Cover
2018-08-061,9903,05065.2459Short
2018-08-033,00046,3116.4779Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTGEF.


About Portage Biotech Inc (OTC: PTGEF)

Logo for Portage Biotech Inc (OTC: PTGEF)

Portage is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. Following proof of concept, Portage will look to sell or license the products to large pharmaceutical companies for further development and commercialization. Portage has two operating subsidiaries, portage Pharmaceuticals Limited PPL which is wholly owned by Portage and Biohaven Pharmaceutical Holding Company Limited Biohaven in which Portage holds . as at June , . PPL has successfully validated CellPorter , a novel and proprietary cell permeable peptide platform that has been shown to efficiently deliver active biologic agents into cells without disrupting the cell membrane. PPL will be advancing its lead candidate, PPL , to an Investigational New Drug IND application for the topical treatment of Dry Eye Disease and Uveitis. Biohaven is a privately held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. The Company s first drug candidate, BHV , is a novel formulation of a glutamate modulating agent, being developed under FDA b guidelines. Biohaven s second compound, BHV , is an NCE for neurodegenerative and neuropsychiatric disorders.

 

Contact Information

 

 

Current Management

  • Declan Doogan / CEO
    • Has more than years experience in the global pharmaceutical industry. He joined Pfizer in , where he held a number of senior positions in R amp D in the USA, UK and Japan. He retired from Pfizer in as the Senior VP Head of World Development. Was interim CEO and CMO at Amarin. Holds visiting professorships at Glasgow, Kitasato Tokyo and Cork Universities . He received his Medical degree from Glasgow University.
  • Kamlesh Shah / CFO
    • Senior financial executive with over years of corporate finance, Was senior manager with two of the largest accounting firms, Ernst amp Young and Price Waterhouse Coopers. Worked in industry under various roles from an office manager to CEO, CFO of public companies.
  • Gregory Bailey / Chairman
    • Former director and financier of Medivation Inc. MDVN: NASDAQ . Cofounder, of Ascent Healthcare Solutions: VirnetX Inc internet security VHC: AMEX and Duramedic Inc. Has Medical Doctorate from the University of Western Ontario.
  • Declan Doogan /
    • Has more than years experience in the global pharmaceutical industry. He joined Pfizer in , where he held a number of senior positions in R amp D in the USA, UK and Japan. He retired from Pfizer in as the Senior VP Head of World Development. Was interim CEO and CMO at Amarin. Holds visiting professorships at Glasgow, Kitasato Tokyo and Cork Universities . He received his Medical degree from Glasgow University.
  • James Mellon /
    • Director of multiple public companies: In the biopharma sector Miraculins, Plethora Solutions, and the Summit Corporation. Chairman of AIM listed Port Erin Biopharma Investments, a fund specializing in biopharma investments The author of the bestselling book Cracking the Code . Other listed company directorships include chairman of Manx Financial Group, cochairman of both Regent Pacific Group and West African Mining Corporation, and a board member of Brazilian Gold Corporation, Charlemagne Capital and Condor Resources.
  • Steven Mintz /
    • Senior financial consultant qualified as CA since and received BA Economics and accounting from University of Toronto in . Obtained Trustee in Bankruptcy license in . Practiced public accounting at a large accounting firm between to , then employed by a boutique bankruptcy firm from to and since , has been a financial consultant to individuals and private and public companies. CEO and CFO of Dominion General Investment Corporation. Officer and director of several public and private companies.
  • Kamlesh Shah /
    • Senior financial executive with over years of corporate finance, Was senior manager with two of the largest accounting firms, Ernst amp Young and Price Waterhouse Coopers. Worked in industry under various roles from an office manager to CEO, CFO of public companies.
  • Ian Walters /
    • Ian Walters, M.D., M.B.A. is an experienced life science entrepreneur who has helped found and launched several life science companies. He is currently the founder and CEO of SalvaRx LON: SALV and iOx Therapeutics, a SalvaRx portfolio company. He is also the Chief Medical Officer for Intensity Therapeutics. Dr Walters has led drug development teams in several therapeutic areas and contributed to bringing blockbuster products to market, including Opdivo , Yervoy , and Velcade . While Dr. Walters worked at BMS, he managed physicians overseeing the international development of more than oncology compounds as well as biomarker and companion diagnostic work. He also was a core member of BMS s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, and clinical collaborations. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.

Current Share Structure

  • Market Cap: $29,718,534 - 03/09/2018
  • Issue and Outstanding: 260,688,894 - 03/31/2017
  • Float: 122,300,861 - 07/25/2016

 


Recent Filings from (OTC: PTGEF)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 05 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 05 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 23 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: January, 10 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 09 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 08 2018

 

 


Daily Technical Chart for (OTC: PTGEF)

Daily Technical Chart for (OTC: PTGEF)


Stay tuned for daily updates and more on (OTC: PTGEF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PTGEF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTGEF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of PTGEF and does not buy, sell, or trade any shares of PTGEF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/